Analyst Price Target is $168.64
▲ +31.34% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $168.64, with a high forecast of $190.00 and a low forecast of $135.00. The average price target represents a 31.34% upside from the last price of $128.40.
Current Consensus is
The current consensus among 12 contributing investment analysts is to buy stock in Guardant Health. This Buy consensus rating has held steady for over two years.
Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Redwood City, CA.